La catena delle opzioni mostra i dati chiave delle opzioni azionarie di GrowGeneration a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per GrowGeneration..

GrowGeneration (NASDAQ:GRWG) Azioni, Catena delle Opzioni

GrowGeneration

GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.

GrowGeneration Corp

Telsey Advisory Group analyst Joseph Feldman maintains Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Outperform and maintains $455 price target.

News

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Home Depot, Maintains $455 Price Target

WIIM

METC

Ramaco Resources shares are trading higher after the company announced it will release updated information regarding its Brook mine rare earth and critical minerals project on July 1st.

INDV

Indivior shares are trading higher after the company was added to the Russell 2000 index. Additionally, Craig-Hallum raised its price target on the stock from $15 to $22.

H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>), highlighting the company&#8217;s &#8220;rebirth&#8221; following the in-licensing of telitacicept.
On Thursday, the company announced a strategic licensing agreement and a major capital raise to support its <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46120176/why-this-biotech-stock-just-doubled-in-a-single-day" rel="noreferrer noopener">push into autoimmune therapies</a>.
Vor Bio signed an exclusive global licensing deal with RemeGen Co., Ltd., giving it rights outside Greater China to develop and commercialize telitacicept, a dual-action fusion protein already approved in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46108474/puretech-founded-entity-vor-bio-announces-exclusive-global-license-agreement-with-remegen-for-late" rel="noreferrer noopener">China for multiple autoimmune disorders</a>.
Also Read: <a href="https://www.benzinga.com//node/46120176">Why This Biotech Stock Just Doubled In A Single Day</a>
Under the agreement, Vor will pay $125 million upfront, $45 million in cash, $80 million in stock warrants, and potential milestone payments exceeding $4 billion and tiered royalties.
The company also announced that Jean-Paul Kress has stepped in as CEO and Chairman, replacing Dr. Robert Ang, who will stay on as a strategic advisor through October.
Commenting on the development, HC Wainwright stated, &#8220;Overall, we are encouraged by the quick resurrection of the company by the board and the management as this transaction brings a de-risked asset that could be commercialized in the US starting mid-2028.&#8221;
Analyst Swayampakula Ramakanth upgraded Vor Biopharma from Neutral to Buy on Monday with a <a target="_blank" href="https://www.benzinga.com/quote/VOR/analyst-ratings" rel="noreferrer noopener">price forecast of $3</a>.
Ramakanth highlights the significant market opportunity for telitacicept in generalized myasthenia gravis (gMG). Based on a 2018 survey of Medicare data, an estimated 82,700 people in the U.S. had gMG in 2021, with approximately 75% receiving treatment.
The analyst projects that if telitacicept is priced at $225,000 per patient yearly and captures 15% of the U.S. market, peak annual sales could reach $1.8 billion.
Furthermore, the analyst says, should the drug successfully launch in the EU and Japan, with commercial partners managing sales outside the U.S. and achieving a 10% market share, it could generate an additional $2.7 billion in combined sales and royalties.
While RemeGen is conducting a Phase 3 trial of telitacicept for lupus (SLE) in the U.S. and EU, the analyst notes that Vor Biopharma currently lacks a defined strategy for marketing the drug for SLE. Consequently, any potential sales from this indication are not factored into Vor&#8217;s current projections.
Price Action: VOR stock is up 49.1% at $1.58 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/46165307/us-credit-rating-would-fall-if-trumps-big-beautiful-bill-is-approved-says-thomas-massie-heres-what-it-means-for-americans" target="_blank" rel="noreferrer noopener">US Credit Rating Would Fall If Trump&#8217;s Big Beautiful Bill Is Approved, Says Thomas Massie: Here&#8217;s What It Means For Americans</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Upgrades

Health Care

Movers

Trading Ideas

General

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

TROX

Tronox Holdings shares are trading lower after BMO Capital downgraded the stock from Market Perform to Underperform and cut its price target from $7 to $3.

Leonardo DRS shares are trading higher after Goldman Sachs initiated coverage on the stock with a Buy rating and announced a price target of $49.

Wall Street veteran and Fundstrat co-founder Tom Lee is set to bring Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) into the spotlight, with plans to position BitMine Immersion Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) as the &#8216;<a href="https://www.benzinga.com/crypto/25/06/46089976/tom-lee-says-microstrategy-could-outpace-bitcoin-gains-goes-up-a-lot-more-as-btc-rallies">MicroStrategy of Ethereum.</a>&#8216;
What Happened: In an CNBC Squawk <a href="https://www.cnbc.com/video/2025/06/30/fundstrats-tom-lee-on-being-named-chairman-of-bitmine-immersion-technologies.html">interview</a> on June 30, Lee announced his new role as chairman of BitMine, a small-cap Bitcoin mining firm valued at $26 million. 
Under his leadership, BitMine will pivot from being purely a miner to an Ethereum-focused treasury company, adopting ETH as its primary reserve asset.
To kick off the transition, BitMine has announced a $250 million private placement, which will be used to accumulate Ether while maintaining its existing Bitcoin mining operations.
Lee stressed Ethereum's vital role in powering the stablecoin ecosystem, calling stablecoins the &#8220;ChatGPT of crypto&#8221; due to their rapid and widespread adoption. 
By holding ETH, Lee believes BitMine can help support and benefit from the infrastructure underpinning stablecoins.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46175268/ethereum-traders-target-4000-in-summer-whats-fueling-the-optimism">Ethereum Traders Target $4,000 In Summer: What&#8217;s Fueling The Optimism?</a>
Why It Matters: BitMine will begin tracking ETH-per-share as its principal performance metric, emulating how Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) uses BTC-per-share to communicate shareholder value. 
The firm plans to grow this figure via Ethereum price appreciation, reinvested cash flows, and strategic capital market activities.
This marks a shift in corporate treasury strategies, with a growing number of firms now exploring Ether and Solana-based reserves. Companies like SharpLink Gaming and DeFi Development have already started integrating ETH into their treasuries.
Just last week, <a href="https://www.benzinga.com/crypto/25/06/46089976/tom-lee-says-microstrategy-could-outpace-bitcoin-gains-goes-up-a-lot-more-as-btc-rallies">Lee praised MicroStrategy's model</a>, noting its ability to outperform Bitcoin through clever capital deployment, including the issuance of convertible debt at near-zero interest rates to acquire more BTC. 
He believes BitMine can replicate that success, but with Ethereum at its core.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46139888/michael-saylor-says-bitcoin-treasury-companies-can-unlock-even-more-growth-heres-how">Michael Saylor Says Bitcoin Treasury Companies Can Unlock Even More Growth: Here&#8217;s How</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

BMNR

MSTR

Inside Tom Lee's Plan To Build 'MicroStrategy Of Ethereum' At BitMine

Last week, CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) said one of its large dialysis organization (LDO) customers has started ordering, with implementation planned for the second half of 2025.
The company said that implementation of its DefenCath catheter lock solution will initially target at least 50% more patients than previously planned, with an opportunity for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46048778/cormedix-inc-announces-customer-implementation" rel="noreferrer noopener">even further expansion</a>.
As a result, CorMedix made adjustments to its agreement with the customer and now expects a modest revenue increase in June with continued growth anticipated in the second half of the year.
The company updated its second-quarter net sales guidance from $31 million to a range of $35 million to $40 million to reflect the expected increased use of product by the customer.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46059139/cormedix-stock-hits-new-52-week-high-on-updated-guidance-the-details" rel="noreferrer noopener">CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details</a>
DefenCath is a catheter <a target="_blank" href="https://www.defencath.com/" rel="noreferrer noopener">lock</a> solution to reduce the risk of catheter-related bloodstream infections (CRBSIs) in adults with kidney failure undergoing chronic hemodialysis via a central venous catheter. The FDA approved the product in 2023.
HC Wainwright initiated coverage on CorMedix, citing &#8220;good things are worth the wait&#8230;&#8221;
Analyst Brandon Folkes wrote, &#8220;We believe DefenCath&#8217;s strong launch to date is indicative of good results these operators are seeing in practice, and in our view, this real world experience, along with the more formal real-world study DefenCath in undertaking is likely to support a more durable DefenCath long term revenue stream in CRBSIs than is currently reflected.&#8221;
HC Wainwright initiated with a Buy rating, <a target="_blank" href="https://www.benzinga.com/quote/CRMD/analyst-ratings" rel="noreferrer noopener">with a price forecast of $20</a>.
The company is in the initial t-year of the Transitional Drug Add-on Payment Adjustment (TDAPA) period and will enjoy a further three years post this initial reimbursement period, albeit at a lower level. The analyst sees potential for further outperformance in CorMedix stock.
Folkes added, &#8220;As we see longer-term revenue expectations come closer together and remove the uncertainty and wide variation, we believe CRMD investors could be further rewarded.&#8221;
On Friday, CorMedix priced its previously announced underwritten public offering of 6.6 million, with gross proceeds expected to be<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46136775/cormedix-inc-announces-pricing-of-public-offering-of-common-stock" rel="noreferrer noopener"> approximately $85 million</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/management/25/06/46166087/mark-cuban-slams-insurers-over-high-deductibles-urges-josh-hawley-to-change-the-game-with-two-part-plan" target="_blank" rel="noreferrer noopener">Mark Cuban Slams Insurers Over High Deductibles, Urges Josh Hawley To &#8216;Change The Game&#8217; With Two-Part Plan</a></li>
</ul>
Photo: MacroEcon via Shutterstock.

CRMD

CorMedix Analyst Says Investors Could Be Further Rewarded

<a href="https://truthsocial.com/@realDonaldTrump/114773696636727417">https://truthsocial.com/@realDonaldTrump/114773696636727417</a>

President Trump Posts On Truth Social "I apologize for the long wait on the Faith Leaders Conference Call. AT&T ought to get its act together. Please pass along the word to the tens of thousands of people who are there. We may have to reschedule the call, but we'll use another carrier the next time. AT&T obviously doesn't know what they're doing!"

New Fortress Energy shares are trading higher after the company announced it signed an LNG supply contract extension with Puerto Rico's government.

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/topic/nvidia" target="_blank" rel="noreferrer noopener">stock surged 44%</a> in the previous three months while the PHLX Semiconductor Sector Index (SOX), which Nvidia is part of, gained 29.41% during the period.
The stock is currently trading near its 52-week high of $158.71.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46149318/microsofts-next-gen-ai-chip-still-lags-nvidias-blackwell-postpones-launch" target="_blank" rel="noreferrer noopener">Microsoft&#8217;s Next-Gen AI Chip Still Lags Nvidia&#8217;s Blackwell, Postpones Launch</a>
In May, Nvidia reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong" rel="noreferrer noopener">first-quarter revenue</a> growth of 69% to $44.1 billion, topping the Street consensus estimate of $43.2 billion. The revenue increased by 12% sequentially.
Adjusted EPS of 96 cents topped the analyst consensus estimate of 88 cents.
Nvidia faced an export ban on H20 products to China on April 9. The company said it incurred a $4.5 billion charge in the first quarter related to H20 excess inventory and purchase obligations.&nbsp;
Nvidia forecasted second-quarter revenue of $45 billion, plus or minus 2%, versus&nbsp;estimates of $45.78 billion. The company noted its outlook reflects a loss of approximately $8 billion in H20 revenue due to the export control limitations.
Multiple Wall Street firms <a target="_blank" href="https://www.benzinga.com/quote/NVDA/analyst-ratings" rel="noreferrer noopener">raised their price targets</a> on the company after the results.
Nvidia has a consensus price target of&nbsp;$178.46&nbsp;based on the ratings of&nbsp;38&nbsp;analysts. The high is&nbsp;$250,&nbsp;issued by&nbsp;Loop Capital&nbsp;on&nbsp;June 25, 2025.&nbsp;
Nvidia made at least one acquisition during the quarter. As of June 27, Nvidia acquired&nbsp;Canadian AI startup, CentML, <a href="https://www.benzinga.com/m-a/25/06/46149909/nvidia-ai-acquisition" target="_blank" rel="noreferrer noopener">for undisclosed terms</a>.&nbsp;
CentML specializes in&nbsp;optimizing AI, offering innovative solutions that significantly enhance efficiency and performance.
The chip designer tapped CentML CEO Gennady Pekhimenko as a senior director for AI software at Nvidia.
CentML plans to optimize both model training and inference by running models after they&#8217;ve been trained.
Graphics processing units (GPUs) are also heavily used in inference today, and Pekhimenko noted them as a potential avenue of growth for the company.
Wedbush&#8217;s Dan Ives&nbsp;indicated&nbsp;that Nvidia is on a path to a <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45668727/nvidia-stock-is-surging-thursday-whats-fueling-the-move" target="_blank" rel="noreferrer noopener">$4 trillion market cap</a>, eventually reaching $5 trillion, backed by increasing AI spending.&nbsp;
Deepwater&#8217;s Gene Munster&nbsp;highlighted Nvidia&#8217;s core business&#8217;s impressive growth when excluding the impacts of the China chip restrictions.
Bank of America analyst&nbsp;Vivek Arya&nbsp;estimated that Nvidia&nbsp;holds 80%-85%&nbsp;of the total market for AI data center chips. The Blackwell platform prompted Arya to raise his earnings forecast for the calendar year 2027 to $7.23 per share, which is up 12%. He had projected long-term earnings power of $10 per share, driven by the company's AI hardware moat.
NVDA Price Action:&nbsp;NVDA stock is down slightly at $157.65 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46125295/google-future-wall-street-ai-hype-meets-skepticism" target="_blank" rel="noreferrer noopener">Google Future Divides Wall Street As AI Hype Meets Skepticism</a></li>
</ul>
Photo: Shutterstock

Tech

NVDA

What Is Going On With Nvidia Stock?

<a href="https://truthsocial.com/@realDonaldTrump/114773668772907430">https://truthsocial.com/@realDonaldTrump/114773668772907430</a>

President Trump Posts On Truth Social "I'm doing a major Conference Call with Faith Leaders from all over the Country, and AT&T is totally unable to make their equipment work properly. This is the second time it's happened. If the Boss of AT&T, whoever that may be, could get involved — It would be good. There are tens of thousands of people on the line!"

<a href="https://www.bloomberg.com/news/articles/2025-06-30/eu-to-accept-trump-s-universal-tariff-but-seeks-key-exemptions?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-30/eu-to-accept-trump-s-universal-tariff-but-seeks-key-exemptions?embedded-checkout=true</a>

'EU Wants The US To Commit To Lower Rates On Key Sectors Such As Pharmaceuticals, Alcohol, Semiconductors And Commercial Aircraft; EU Is Also Pushing The US For Quotas And Exemptions To Effectively Lower Washington's 25% Tariff On Automobiles And Car Parts; EU Is Also Pushing The US For Quotas And Exemptions To Effectively Lower Washington's 50% Tariff On Steel And Aluminum'- Bloomberg

HC Wainwright initiated coverage on Aardvark Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) on Monday with a Buy rating and a <a href="https://www.benzinga.com/quote/AARD/analyst-ratings">price forecast of $40</a>.
In February, Aardvark Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) priced an initial public offering of 5.9 million at $16 per share, with approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43682266/aardvark-therapeutics-announces-pricing-of-initial-public-offering" rel="noreferrer noopener">$94.2 million in gross proceeds</a>.
Aardvark is a&nbsp;clinical-stage biopharmaceutical company that develops novel, small-molecule therapeutics to activate innate homeostatic pathways for metabolic diseases.
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/46175777/fda-flags-major-safety-concerns-for-argenxs-nerve-disorder-drug-stock-falls">FDA Flags Major Safety Concerns For Argenx&#8217;s Nerve Disorder Drug, Stock Falls</a>
Aardvark&#8217;s lead product candidate, ARD-101, targets Bitter Taste Receptors (TAS2Rs) expressed in the gut lumen, inducing secretion of endogenous signaling molecules, including the satiety hormone cholecystokinin (CCK), which in turn activates gut-brain signals to suppress the sensation of hunger.
Unlike many existing obesity treatments that act systemically and can cause significant gastrointestinal (GI) side effects like nausea, vomiting, and diarrhea, ARD-101 targets specific receptors in the gut.
ARD-101 aims to reduce hunger and facilitate weight loss without the typical systemic side effects. Importantly, its gut-restricted nature means minimal systemic exposure, potentially minimizing off-target effects and preserving lean muscle mass, which is a common concern with some weight loss methods.
The drug candidate has entered Phase 3 development for hyperphagia associated with Prader-Willi Syndrome. Data readout is expected in early 2026. The company holds Orphan Drug Designation for ARD-101 in PWS.
Aardvark believes that its existing cash, cash equivalents, and short-term investments, together with the proceeds from the IPO, will be sufficient to fund projected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45420113/aardvark-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-highlight" rel="noreferrer noopener">operations into 2027</a>.
Analyst Raghuram Selvaraju noted that there is only one branded medication currently approved in PWS, namely, Vykat XR (diazoxide choline extended-release), launched in April 2025, which has a list price of over $466K in the U.S. 
Accordingly, the analyst feels that the pricing and competitive landscape dynamics appear favorable, even if the target patient population is small (roughly 20K patients in the U.S.)
FDA approved Soleno Therapeutics, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44512290/soleno-therapeutics-secures-fda-approval-for-its-first-commercial-drug-for-rare-genetic-disorder" rel="noreferrer noopener">age and older with PWS</a>.
Selvaraju believes that &#8220;ARD-101 could achieve robust market share even if it does not have comparable or superior efficacy to existing approved agents, if it proves the hypothesis that the mechanism of action ought to yield significantly better safety and tolerability (particularly with respect to GI side effects).&#8221; 
Beyond Prader-Willi Syndrome, ARD-101 is also being evaluated in the Phase 2 HONOR trial for patients with hypothalamic obesity (HO). The analyst views ARD-101 as an &#8220;intriguing treatment alternative for HO patients because of its oral route of administration and benign safety profile.&#8221; Hypothalamic obesity is a challenging condition with limited approved treatments.
Price Action: AARD stock was up 4.11% at $13.94 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46167825/bitmine-immersion-technologies-stock-is-soaring-monday-whats-going-on" target="_blank" rel="noreferrer noopener">BitMine Immersion Technologies Stock Is Soaring Monday: What&#8217;s Going On?</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Initiation

AARD

SLNO

Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress

Investors with a lot of money to spend have taken a bullish stance on Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HWM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Howmet Aerospace.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 33%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $196,200, and 5 are calls, for a total amount of $269,633.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $155.0 to $210.0 for Howmet Aerospace over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Howmet Aerospace's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Howmet Aerospace's whale activity within a strike price range from $155.0 to $210.0 in the last 30 days. 
<h3>Howmet Aerospace Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751306490_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HWM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.1</td>
<td>$24.7</td>
<td>$25.1</td>
<td>$200.00</td>
<td>$67.7K</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>HWM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$6.4</td>
<td>$6.2</td>
<td>$6.4</td>
<td>$210.00</td>
<td>$64.0K</td>
<td align="right">806</td>
<td align="right">206</td>
</tr>
<tr>
<td>HWM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.7</td>
<td>$27.6</td>
<td>$27.7</td>
<td>$175.00</td>
<td>$58.1K</td>
<td align="right">131</td>
<td align="right">21</td>
</tr>
<tr>
<td>HWM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/17/25</td>
<td>$7.3</td>
<td>$4.2</td>
<td>$5.8</td>
<td>$210.00</td>
<td>$58.0K</td>
<td align="right">806</td>
<td align="right">0</td>
</tr>
<tr>
<td>HWM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$5.7</td>
<td>$5.2</td>
<td>$5.15</td>
<td>$160.00</td>
<td>$51.5K</td>
<td align="right">444</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Howmet Aerospace</h3>
Howmet Aerospace Inc produces products that are majorly used in aerospace, commercial transportation, and industrial and other markets. The company seeks to provide its customers with solutions by offering differentiated products such as airfoils with cooling and coatings for extreme temperature applications, specially designed fasteners for lightweight composite airframe construction, reduced assembly costs, lightning strike protection, and lightweight aluminum commercial wheels. It has four reportable segments namely, Engine Products, Fastening Systems, Engineered Structures, and Forged Wheels.
<h3>Where Is Howmet Aerospace Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,109,803, with HWM's price down by 0.0%, positioned at $184.9.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
<h3>What The Experts Say On Howmet Aerospace</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $196.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Howmet Aerospace, maintaining a target price of $200. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Howmet Aerospace with a target price of $192. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Howmet Aerospace, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Howmet Aerospace Unusual Options Activity For June 30

Financial giants have made a conspicuous bearish move on IonQ. Our analysis of options history for IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) revealed 37 unusual trades.
Delving into the details, we found 45% of traders were bullish, while 51% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $555,310, and 30 were calls, valued at $5,701,734.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $75.0 for IonQ over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for IonQ options trades today is 2359.38 with a total volume of 57,667.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for IonQ's big money trades within a strike price range of $20.0 to $75.0 over the last 30 days.
<h3>IonQ Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751306485_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.3</td>
<td>$5.2</td>
<td>$5.21</td>
<td>$70.00</td>
<td>$2.0M</td>
<td>3.3K</td>
<td>4.0K</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$12.4</td>
<td>$12.25</td>
<td>$12.25</td>
<td>$34.00</td>
<td>$1.9M</td>
<td>7.6K</td>
<td>2</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.05</td>
<td>$13.0</td>
<td>$13.0</td>
<td>$40.00</td>
<td>$260.0K</td>
<td>2.8K</td>
<td>330</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/03/25</td>
<td>$2.7</td>
<td>$2.09</td>
<td>$2.1</td>
<td>$41.00</td>
<td>$214.8K</td>
<td>2.5K</td>
<td>1.7K</td>
</tr>
<tr>
<td>IONQ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$8.15</td>
<td>$8.05</td>
<td>$8.15</td>
<td>$47.00</td>
<td>$163.0K</td>
<td>1.2K</td>
<td>209</td>
</tr>
</tbody>
</table>

<h3>About IonQ</h3>
IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.
In light of the recent options history for IonQ, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is IonQ Standing Right Now?</h3>
<ul>
<li>With a trading volume of 23,500,794, the price of IONQ is up by 5.91%, reaching $42.63.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 37 days from now.</li>
</ul>
<h3>What Analysts Are Saying About IonQ</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $50.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Benchmark has revised its rating downward to Buy, adjusting the price target to $50. 
&#x2A; An analyst from Benchmark downgraded its action to Buy with a price target of $50. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $50. 
&#x2A; An analyst from Benchmark downgraded its action to Buy with a price target of $50. 
&#x2A; Consistent in their evaluation, an analyst from Benchmark keeps a Buy rating on IonQ with a target price of $50. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for IonQ, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

IONQ

IonQ Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRDO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Credo Technology Group.
This isn't normal.
The overall sentiment of these big-money traders is split between 12% bullish and 62%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $127,220, and 6 are calls, for a total amount of $217,540.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $100.0 for Credo Technology Group over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Credo Technology Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Credo Technology Group's significant trades, within a strike price range of $70.0 to $100.0, over the past month.
<h3>Credo Technology Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751306479_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRDO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$5.1</td>
<td>$5.0</td>
<td>$5.1</td>
<td>$85.00</td>
<td>$101.9K</td>
<td>734</td>
<td align="right">204</td>
</tr>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$6.4</td>
<td>$6.3</td>
<td>$6.35</td>
<td>$100.00</td>
<td>$63.5K</td>
<td>1.0K</td>
<td align="right">364</td>
</tr>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$39.9</td>
<td>$36.0</td>
<td>$36.8</td>
<td>$85.00</td>
<td>$36.8K</td>
<td>323</td>
<td align="right">10</td>
</tr>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$6.8</td>
<td>$6.6</td>
<td>$6.65</td>
<td>$100.00</td>
<td>$33.2K</td>
<td>1.0K</td>
<td align="right">75</td>
</tr>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$32.2</td>
<td>$29.8</td>
<td>$30.79</td>
<td>$70.00</td>
<td>$30.7K</td>
<td>423</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Credo Technology Group</h3>
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
Following our analysis of the options activities associated with Credo Technology Group, we pivot to a closer look at the company's own performance.
<h3>Where Is Credo Technology Group Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,345,296, with CRDO's price down by -0.76%, positioned at $92.78.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 65 days.</li>
</ul>
<h3>What Analysts Are Saying About Credo Technology Group</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $85.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Credo Technology Group, which currently sits at a price target of $80. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Credo Technology Group with a target price of $85. 
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Credo Technology Group, targeting a price of $90. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Credo Technology Group, targeting a price of $85. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Credo Technology Group with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

CRDO

This Is What Whales Are Betting On Credo Technology Group

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Par Pacific Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PARR#NYSE">PARR</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Par Pacific Hldgs and provided 12-month price targets. The average target is $22.15, accompanied by a high estimate of $30.00 and a low estimate of $14.75. This upward trend is apparent, with the current average reflecting a 7.52% increase from the previous average price target of $20.60.
<img src="https://www.benzinga.com/files/images/story/2025/1751306474_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Par Pacific Hldgs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Justin Jenkins</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.75</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Par Pacific Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Par Pacific Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Par Pacific Hldgs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Par Pacific Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PARR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Par Pacific Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Par Pacific Hldgs</h2>
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
<h3>Key Indicators: Par Pacific Hldgs's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Par Pacific Hldgs faced challenges, resulting in a decline of approximately -11.9% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.74%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Par Pacific Hldgs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.64% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.8%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.47, Par Pacific Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PARR

Where Par Pacific Hldgs Stands With Analysts

Across the recent three months, 22 analysts have shared their insights on DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $219.68, a high estimate of $280.00, and a low estimate of $175.00. Surpassing the previous average price target of $215.29, the current average has increased by 2.04%.
<img src="https://www.benzinga.com/files/images/story/2025/1751306465_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of DoorDash among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$260.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Michael McGovern</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$198.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$196.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$198.00</td>
<td>$201.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Michael McGovern</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$235.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$201.00</td>
<td>$198.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to DoorDash. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DoorDash compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for DoorDash's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DoorDash's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DASH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DoorDash analyst ratings.</a>
<h2>Get to Know DoorDash Better</h2>
Founded in 2013 and headquartered in San Francisco, DoorDash is an online delivery demand aggregator. Consumers can use its app to order food items on-demand for delivery or in-store from merchants. Through the acquisition of Wolt in 2022, the firm also provides this service in Europe and Asia. DoorDash creates a marketplace for merchants to establish a presence online, market their offerings, and meet demand through delivery. The firm provides similar service to nonrestaurant businesses, such as grocery, retail, and pet supplies. Dash is also rolling out nascent technology like drone delivery in an effort to continually innovate and provide the best possible service to supply-side and demand-side contingents of its marketplace.
<h3>DoorDash: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: DoorDash displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 20.65%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: DoorDash's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.37% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): DoorDash's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.38%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): DoorDash's ROA stands out, surpassing industry averages. With an impressive ROA of 1.46%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DASH

22 Analysts Assess DoorDash: What You Need To Know

In the last three months, 4 analysts have published ratings on GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $95.75, a high estimate of $115.00, and a low estimate of $78.00. Observing a downward trend, the current average is 12.42% lower than the prior average price target of $109.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1751306452_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive GeneDx Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$78.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to GeneDx Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of GeneDx Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of GeneDx Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of GeneDx Holdings's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WGS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GeneDx Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind GeneDx Holdings</h2>
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
<h3>Breaking Down GeneDx Holdings's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining GeneDx Holdings's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.56% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: GeneDx Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -7.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.6%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): GeneDx Holdings's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.51%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: GeneDx Holdings's debt-to-equity ratio is below the industry average at 0.45, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

GrowGeneration

GrowGeneration (GRWG) Opzioni

GrowGeneration (NASDAQ:GRWG) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO